Insiders · IOVA

Michael Weiser

Director at Iovance Biotherapeutics, Inc. (IOVA)

Michael Weiser has filed 8 insider reports with the SEC since July 2021, as director at Iovance Biotherapeutics, Inc. (IOVA). Michael Weiser made no open-market purchases or sales in the last 12 months. The latest filing, on June 18, 2026, reports grant or award at Iovance Biotherapeutics, Inc. (IOVA).

Filings
8
Companies
1
Bought on market
$68K
Sold on market
None

Companies where Michael Weiser is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Iovance Biotherapeutics, Inc. logo
IOVA
Iovance Biotherapeutics, Inc.
Director112,632$68K$6.80$7.55+11%Jun 18, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.

Every filing

Compare Michael Weiser with

Other insiders at the same companies

Questions about Michael Weiser

What is Michael Weiser's role at Iovance Biotherapeutics, Inc.?
Michael Weiser reports to the SEC as director at Iovance Biotherapeutics, Inc. (IOVA), according to the latest filing on June 18, 2026.
How many shares does Michael Weiser own?
After the latest filing that states it, Michael Weiser directly owned 112,632 shares of Iovance Biotherapeutics, Inc. (IOVA). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Michael Weiser bought or sold stock recently?
The most recent open-market purchase was on May 31, 2022: bought 10,000 shares of Iovance Biotherapeutics, Inc. (IOVA) for $68K at an average of $6.80.
How do I get alerts when Michael Weiser files?
Follow Michael Weiser on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Michael Weiser (SEC CIK 0001221449). Totals count each trade once, skipping amendments whose original is on file, from Jul 1, 2021 on. View on SEC EDGAR